94-22034. Animal Drug Export; ImmiticideRegister (Melarsomine Dihydrochloride) Sterile Powder  

  • [Federal Register Volume 59, Number 172 (Wednesday, September 7, 1994)]
    [Unknown Section]
    [Page 0]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 94-22034]
    
    
    [[Page Unknown]]
    
    [Federal Register: September 7, 1994]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Food and Drug Administration
    [Docket No. 94N-0310]
    
     
    
    Animal Drug Export; Immiticide (Melarsomine 
    Dihydrochloride) Sterile Powder
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing that 
    Rhone Merieux, Inc., has filed an application requesting approval for 
    export to France, solely for the purpose of further export to Italy and 
    Australia, of the animal drug Immiticide (melarsomine 
    dihydrochloride) sterile powder for use as an injectable for dogs.
    
    ADDRESSES: Relevant information on this application may be directed to 
    the Dockets Management Branch (HFA-305), Food and Drug Administration, 
    rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact 
    person identified below. Any future inquiries concerning the export of 
    nonfood animal drugs under the Drug Export Amendments of 1986 should 
    also be directed to the contact person.
    
    FOR FURTHER INFORMATION CONTACT: Gregory S. Gates, Center for 
    Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 
    Standish Pl., Rockville, MD 20855, 301-594-1617.
    
    SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of 
    the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) 
    provide that FDA may approve applications for the export of drugs that 
    are not currently approved in the United States. Section 802(b)(3)(B) 
    of the act sets forth the requirements that must be met in an 
    application for approval. Section 802(b)(3)(C) of the act requires that 
    the agency review the application within 30 days of its filing to 
    determine whether the requirements of section 802(b)(3)(B) have been 
    satisfied. Section 802(b)(3)(A) of the act requires that the agency 
    publish a notice in the Federal Register within 10 days of the filing 
    of an application for export to facilitate public participation in its 
    review of the application. To meet this requirement, the agency is 
    providing notice that Rhone Merieux, Inc., 115 Transtech Dr., Athens, 
    GA 30601, has filed application number 6203 requesting approval for 
    export to France of the animal drug Immiticide (melarsomine 
    dihydrochloride) sterile powder. The product is intended for use in 
    dogs for treatment of Dirofilaria immitis infections. The application 
    was received and filed in the Center for Veterinary Medicine on August 
    10, 1994, which shall be considered the filing date for purposes of the 
    act.
        Interested persons may submit relevant information on the 
    application to the Dockets Management Branch (address above) in two 
    copies (except that individuals may submit single copies) and 
    identified with the docket number found in brackets in the heading of 
    this document. These submissions may be seen in the Dockets Management 
    Branch between 9 a.m. and 4 p.m., Monday through Friday.
        The agency encourages any person who submits relevant information 
    on the application to do so by September 19, 1994, and to provide an 
    additional copy of the submission directly to the contact person 
    identified above, to facilitate consideration of the information during 
    the 30-day review period.
        This notice is issued under the Federal Food, Drug, and Cosmetic 
    Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the 
    Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the 
    Center for Veterinary Medicine (21 CFR 5.44).
    
        Dated: August 24, 1994.
    Robert C. Livingston,
    Director, Office of New Animal Drug Evaluation, Center for Veterinary 
    Medicine.
    [FR Doc. 94-22034 Filed 9-6-94; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
09/07/1994
Department:
Food and Drug Administration
Entry Type:
Uncategorized Document
Action:
Notice.
Document Number:
94-22034
Pages:
0-0 (1 pages)
Docket Numbers:
Federal Register: September 7, 1994, Docket No. 94N-0310